Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins

Bioanalysis

Volumn 7, Issue 11, 2015, Pages 1389-1395

  Duggan, Jeffrey X ^a   Vazvaei, Faye ^b   Jenkins, Rand ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Roche Innovation Center New York   (United States)

^c Chromatographic Sciences PPD Bioanalytical Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STABILITY; RECEPTOR BINDING ASSAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; VALIDATION PROCESS; HUMAN; METABOLISM; PROCEDURES; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PROTEIN;

CHROMATOGRAPHY, LIQUID; HUMANS; INDICATORS AND REAGENTS; PROTEIN STABILITY; PROTEINS; TANDEM MASS SPECTROMETRY; VALIDATION STUDIES AS TOPIC;

EID: 84933557104     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.69     Document Type: Short Survey

References (13)

1. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 3(21), 2459-2480 (2011).
2. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011).
3. Hustoft H, Malerod H, Wilson S, Reubsaet L, Lundanes E, Greibrokk T. A critical review of trypsin digestion for LC- MS Based proteomics In: Integrative Proteomics. Leung HC (Ed.) Tech Publishers, Shanghai, China. 73-92 (2012).
4. Becker J, Hoofnagle A. Replacing immunoassays with digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis 4(3) 281-290 (2012).
5. Whiteaker J, Zhao L, Abbatiello S et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 10(4), 1-10 (2011).
6. Vazvaei F, Duggan JX. Validation of LC-MS/MS bioanalytical methods for protein therapeutics. Bioanalysis 6(13), 1739-1742 (2014).
7. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). www.ema.europa.eu
8. Guideline on Bioanalytical Method Validation. European Medicines Agency, London, UK (2011). www.ema.europa.eu
9. Guidance for Industry: bioanalytical Method Validation. US FDA, Rockville, MD, USA (2001). www.fda.gov
10. Bioanalytical Method Validation. Draft Guidance, US FDA, Rockville, MD, USA (2013). www.fda.gov
11. Jenkins R, Duggan J, Aubry AF et al. Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics. AAPS J. 17(1), 1-16 (2015).
12. Knutsson M, Schmidt R, Timmerman P. LC-MS/MS of large molecules in a regulated bioanalytical environment - which acceptance criteria to apply? Bioanalysis 5(18), 2211-2214 (2013).
13. King LE, Farley E, Imazato M et al. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 16(3), 504-515 (2014).